Neal D. Shore, MD

Carolina Urologic Research Center

Neal D. Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology (SUO), the Large Urology Group Practice Association(LUGPA), and the Bladder Cancer SAdvocacy Network(BCAN). He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee; he is currently a member of the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), World Jnl Urology and serves as Editor, Everyday Urology. He has more than 165 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology,Journal Urology, Urology, BJUI,PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Disclosure information not submitted.

Presentation(s):

• Panel Discussion: What is the Optimal Multidisciplinary Team in 2022: Drafting for the Future

  Friday, May 13, 2022
  8:25 AM – 8:45 AM

• MP27: Prostate Cancer: Advanced (including Drug Therapy) I

  Saturday, May 14, 2022
  10:30 AM – 11:45 AM

• MP27-14: Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide or Placebo Plus Androgen Deprivation Therapy Who Had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial

  Saturday, May 14, 2022
  10:30 AM – 11:45 AM

• MP27-16: Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis from the Randomized Phase 3 HERO Study

  Saturday, May 14, 2022
  10:30 AM – 11:45 AM

• Current Status in mHSPC

  Saturday, May 14, 2022
  1:05 PM – 1:25 PM

• PD35-08: Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies

  Sunday, May 15, 2022
  8:10 AM – 8:20 AM

• International Prostate Forum

  Sunday, May 15, 2022
  8:00 AM – 1:00 PM

• IPF Introductions

  Sunday, May 15, 2022
  8:00 AM – 8:05 AM

• Session IV: Recurrent/Advanced Disease

  Sunday, May 15, 2022
  11:45 AM – 1:00 PM

• Panel Discussion with 5 Minute Updates—Optimized Testing and Therapeutics in Advanced Prostate Cancer

  Sunday, May 15, 2022
  12:30 PM – 1:00 PM

• Case-Based Debate: Do I need to do Repeat TUR for all High Grade NMIBC Patients?

  Sunday, May 15, 2022
  3:00 PM – 3:20 PM

• 077IC - Operationalizing Checkpoint Inhibitors in Urologic Practice

  Monday, May 16, 2022
  10:00 AM – 12:00 PM